Cancer Innova Program

Cancer Innova Program

The Kærtor Foundation and the Scientific Foundation of the Spanish Association Against Cancer, in collaboration with the Galician Innovation Agency (GAIN), the pharmaceutical companies Janssen, of the Johnson & Johnson group, and Lilly have created the CANCER INNOVA Program for the development of new drugs against cancer and for the consolidation of a biotechnological ecosystem close to patients. The imminent incorporation of a second multinational pharmaceutical company is expected.

What is Cancer Innova?

It is an inclusive collaboration program in which public and private entities participate together to promote innovation in cancer. To this end, a drug discovery program has been created in line with the Cancer Mission of the Horizon Europe framework program, which represents a milestone in the biotechnology sector.

Who is the Cancer Innova program aimed at?

To researchers and public or private entities and small companies specializing in cancer mechanisms and who want to apply their research to drug discovery.

Expression of Interest’s Form

The Cancer Innova Program call is divided into three phases: the first is the call for Expressions of Interest (EoI) and selection of projects, the second phase is the incubation of research projects and the third is the acceleration and consolidation of the Projects.